小分子川楝素逆转巨噬细胞介导的免疫抑制以克服胶质母细胞瘤对免疫治疗的耐药
研究在小鼠模型中用化学文库对基因探针标记的巨噬细胞进行功能筛选,发现小分子川楝素(TSN)可逆转巨噬细胞介导的肿瘤免疫抑制,增强T细胞浸润、活化并减少耗竭。化学蛋白质组学与结构分析显示TSN与Hck和Lyn相互作用以消除抑制性巨噬细胞免疫。免疫检查点阻断联合TSN使小鼠同基因胶质母细胞瘤消退,TSN治疗使胶质母细胞瘤对Egfrviii嵌合抗原受体(CAR)T细胞疗法敏感。
要点
- 川楝素(TSN)可重编程巨噬细胞,在小鼠胶质母细胞瘤中增强抗肿瘤免疫。
- TSN与Hck和Lyn相互作用,消除抑制性巨噬细胞免疫。
- 免疫检查点阻断联合TSN使小鼠同基因胶质母细胞瘤消退,TSN使胶质母细胞瘤对Egfrviii CAR T细胞疗法敏感。
核心结论
- TSN可能作为一种治疗性化合物,阻断肿瘤免疫抑制并规避胶质母细胞瘤及其他实体瘤对T细胞免疫治疗的耐药,但需进一步研究。
研究设计与样本
- 研究在小鼠模型中进行,用化学文库对基因探针标记的巨噬细胞进行功能筛选,并开展化学蛋白质组学与结构分析。
主要发现
- TSN逆转巨噬细胞介导的肿瘤免疫抑制,导致T细胞浸润、活化增强并减少耗竭。
- 化学蛋白质组学与结构分析显示TSN与Hck和Lyn相互作用以消除抑制性巨噬细胞免疫。
- 免疫检查点阻断联合TSN诱导小鼠同基因胶质母细胞瘤消退。
- TSN治疗使胶质母细胞瘤对Egfrviii嵌合抗原受体(CAR)T细胞疗法敏感。
局限性
- 原文结论指出TSN的作用需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
T cell-based immunotherapy holds promise for treating solid tumors, but its therapeutic efficacy is limited by intratumoral immune suppression. This immune suppressive tumor microenvironment is largely driven by tumor-associated myeloid cells, including macrophages. Here, we report that toosendanin (TSN), a small-molecule compound, reprograms macrophages to enforce antitumor immunity in glioblastoma (GBM) in mouse models. Our functional screen of genetically probed macrophages with a chemical library identifies that TSN reverses macrophage-mediated tumor immunosuppression, leading to enhanced T cell infiltration, activation, and reduced exhaustion. Chemoproteomic and structural analyses revealed that TSN interacts with Hck and Lyn to abrogate suppressive macrophage immunity. In addition, a combination of immune checkpoint blockade and TSN therapy induced regression of syngeneic GBM tumors in mice. Furthermore, TSN treatment sensitized GBM to Egfrviii chimeric antigen receptor (CAR) T cell therapy. These findings suggest that TSN may serve as a therapeutic compound that blocks tumor immunosuppression and circumvents tumor resistance to T cell-based immunotherapy in GBM and other solid tumors that warrants further investigation.
引用
- Yang F, Zhang D, Jiang H, et al. Small-molecule toosendanin reverses macrophage-mediated immunosuppression to overcome glioblastoma resistance to immunotherapy. Sci Transl Med. 2023. PMID: 36791206. doi:10.1126/scitranslmed.abq3558
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。